About
Our Mission
Our MISSION is to disrupt PRECISION MEDICINE by integrating artificial intelligence into DAILY MEDICAL PRACTICE, in the repositioning of drugs with expired patents, and in the discovery of new and novel biopharmaceuticals.
1. Genetic, genomic, and “omics” diagnostics using computer protocols including artificial intelligence algorithms:
- Preventive Clinical Whole Genome Sequencing + mitochondrial DNA (cWGS + mtDNA) – Asymptomatic individuals with significant clinical-genetic family history.
- Clinical Whole Genome Sequencing + mitochondrial DNA (DNA (cWGS + mtDNA).
- Complex cases, diagnostic odyssey and therapeutic guidance.
- Identification of clinically actionable variants from genome sequencing of families with congenital diseases
- Misdiagnosis and Rare Genetic Syndromes (cWGS + mitochondrial DNA/ Panels)
- Chromosomal Microarray Testing
- Prenatal Testing
- Carrier Screening
- Single Gene Testing
- Noninvasive Prenatal Testing (NIPT)
- Oncology-Oncomics (cWGS / Panels)
- Neurology-Neuromics (cWGS / Panels)
- Cardiology-Cardiomics (cWGS / Panels)
- Immunology-Immunomics (cWGS / Panels)
- Oftalmology – Oftalmomics (cWGS / Panels)
- Dermatology – Dermatomics (cWGS / Panels)
- Hematology – Hematomics (cWGS / Panels)
- Sports Medicine – Deportomics (cWGS / Panels)
- “Omics” complex tests
2. Multi-Omics and Artificial Intelligence-Guided Drug Repositioning.
- Repositionable and novel drugs. Our approach is based on the inclusion of data and consented-biological materials from ethnically diverse individuals and physical artificial intelligence to determine the function of unresolved protein variants in the Homo sapiens genome.
- aiGEN is using multiparametric strategies, including computational strategies of genome-wide associations (GWAS), epigenome profiling, omics-driven signature matching, machine learning (ML), artificial intelligence (AI), deep learning (DL), network analysis, chemical structure analysis (molecular docking), and experimental drug repurposing.
- aiGEN is shedding light on disease-causing genetic variations that differ among less-studied human haplogroups (e.g., Latin American Hispanic, and non-Hispanic, African American, African, Asian, and various ancestral populations).
3. Clinical Decision Support (CDS): Make informed clinical decisions with fast access to the latest evidence-based insights at the point of care.
4. Real-world Evidence: support research findings and inform decision-making by generating real-world insights.
Our Obsession is THE DEMOCRATIZATION of access to updated medicine.
– aiGEN
Our Obsession
aiGEN works tirelessly to democratize access to up-to-date medicine (DATA-DRIVEN MEDICINE/PRECISION MEDICINE), helping to ensure that people from all walks of life have equal access to the latest and most effective diagnostics and treatments for a variety of conditions.
Our Vision
OUR VISION is to be one of the market leaders in the adoption of Data-Driven Medicine, helping people to prevent disease and patients to end their tedious diagnostic odyssey.
Data-driven medicine, also known as precision medicine, has the potential to revolutionize healthcare by tailoring treatments to individual patients based on their unique genetic, environmental, and lifestyle factors.
aiGEN has the potential to improve the lives of countless people by giving them the tools they need to take control of their health and well-being.
Our Team
Dr. Mario Hugo Genero, MD
Co-Founder – CEO
With over 20 years of work experience in Genomic Medicine and world-class Data Science, I am passionate about creating life-changing diagnostics and finding better therapies for patients with serious diseases. I use artificial intelligence algorithms and molecular biomarkers to more accurately assess patients’ risk, prognosis, and therapeutic response.
My great desire is to solve the diagnostic odyssey of patients, mainly children from underrepresented populations in genomic-“omics” databases, suffering from rare diseases, and to be able to offer them new therapeutic solutions.
Ricardo R. Aroza
Co-Founder – Corporate Finance and Strategy Executive Consultant
I have extensive experience in consulting and advisory work on mergers and acquisitions of over 10 years. I have
Provided successful planning, advisory, execution, and integration management services to Walmart, and Thomson Reuters on mergers and acquisitions, strategic investments thru greenfield and brownfield strategies, joint ventures, and other related transactions in Latin America, Europe, and Africa.
With more than five years working in Healthcare and Precision Medicine, I fervently believe that with our contribution we can bring the most disadvantaged and forgotten people closer to the new data-driven medicine, enabling better diagnostics and therapeutic offers.